Drug-delivery research shows early promise
Nanotechnology drug delivery could provide breakthrough in cancer treatment
Amiji and his collaborators from the Colleges of Arts and Sciences and Engineering at the University in Boston, Massachusetts, US have been awarded R21 grants by the National Institutes of Health (NIH) to support their research. The NIH’s R21 programme encourages novel and high-risk/high-reward research by providing support for the early and conceptual stages of project development.
The National Cancer Institute has awarded a two-year, US$350,000 grant to develop more potent therapies for killing cancer cells that become resistant after initial chemotherapeutic treatment.
Amiji, working with chemistry and chemical biology professors Robert Hanson and Max Diem, will explore whether including the cell killer ceramide as a part of chemotherapy will kill tumour cells that are resistant to other treatments. Using nanocarrier technology, the combination treatment would be delivered directly to a cancer cell’s mitochondria to trigger cell death.
The National Institute of Neurological Diseases and Stroke has awarded a two-year, US$475,000 grant to Amiji and chemical engineering professor Rebecca Carrier to examine a ‘nano-emulsion’ system of delivery that will allow drugs to cross the blood-brain barrier. The process could greatly increase the recovery chances of a patient with Parkinson’s or HIV/AIDS, because ‘having a system to get these drug therapies to their appropriate place of action is critical,’ said Amiji.
Current drugs developed for treating brain diseases cannot reach the brain 98% of the time because of the low permeability of the blood-brain barrier. Researchers are investigating whether a nano-sized mixture of water, oil droplets rich in omega-3 fatty acids and curcumin, an Indian spice, will help drugs cross the blood-brain barrier by increasing its permeability.
You may also like
Drug Delivery
Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships
Read moreHovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up
Trending Articles
You may also like
Drug Delivery
Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships
Hovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up
Research & Development
From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater
A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Pharmaceutical
Ardena strengthens executive team to drive its next phase of growth
Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally
Pharmaceutical
Backed by investments exceeding $1 billion, PCI Pharma Services announces major expansion of US sterile fill-finish and drug-device delivery combination capabilities
As pharma manufacturers prioritise US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging